A second drug may join the Alzheimer’s treatment Leqembi on the market by the end of the year: Eli Lilly’s donanemab. Lilly said in a news release that it had completed its US Food and Drug Administration submission for the drug, and expects regulatory action by year’s end.
Third Alzheimer's drug represents 'opening chapter in new era' medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.
Eli Lilly's experimental Alzheimer's drug slows disease, data show washingtonpost.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from washingtonpost.com Daily Mail and Mail on Sunday newspapers.
(CNN) The full approval this month of the Alzheimer’s drug Leqembi marked a historic shift in the treatment of the disease: For the first time, doctors have<a class="excerpt-read-more" href="https://whdh.com/news/second-alzheimers-drug-to-slow-diseases-progression-may-be-approved-in-the-us-this-year/">Read More</a>